The role of the fibroblast growth factor family in bone-related diseases

Chem Biol Drug Des. 2019 Oct;94(4):1740-1749. doi: 10.1111/cbdd.13588. Epub 2019 Aug 4.

Abstract

Fibroblast growth factor (FGF) family members are important regulators of cell growth, proliferation, differentiation, and regeneration. The abnormal expression of certain FGF family members can cause skeletal diseases, including achondroplasia, craniosynostosis syndrome, osteoarthritis, and Kashin-Beck disease. Accumulating evidence shows that FGFs play a crucial role in the growth and proliferation of bone and in the pathogenesis of certain bone-related diseases. Here, we review the involvement of FGFs in bone-related processes and diseases; FGF1 in the differentiation of human bone marrow mesenchymal stem cells and fracture repair; FGF2, FGF9, and FGF18 in osteoarthritis; FGF6 in bone and muscle injury; FGF8 in osteoarthritis and Kashin-Beck disease; and FGF21 and FGF23 on bone regulation. These findings indicate that FGFs are targets for novel therapeutic interventions for bone-related diseases.

Keywords: abnormal expression; bone-related diseases; fibroblast growth factor; targeted therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Bone Diseases / drug therapy
  • Bone Diseases / metabolism*
  • Bone Diseases / pathology
  • Bone Marrow Cells / metabolism*
  • Bone Marrow Cells / pathology
  • Cell Differentiation*
  • Cell Proliferation*
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / metabolism*
  • Humans
  • Mesenchymal Stem Cells / metabolism*
  • Mesenchymal Stem Cells / pathology

Substances

  • FGF23 protein, human
  • Fibroblast Growth Factors
  • Fibroblast Growth Factor-23